

Ying Fen Li, Xian Wei, Song Bai and Meng Lan Lv*

Crystal structure of 1-(2-(1*H*-indol-3-yl)ethyl)-4-benzyl-3-hydroxy-3,6-diphenylpiperazine-2,5-dione, C₃₃H₂₉N₃O₃




Table 1: Data collection and handling.

Crystal:	Colorless block
Size:	0.30 × 0.28 × 0.27 mm
Wavelength:	Mo K α radiation (0.71073 Å)
μ :	0.08 mm ⁻¹
Diffractometer, scan mode:	Bruker Apex-II, φ and ω
$\theta_{\max}$, completeness:	25.0°, 99%
$N(hkl)_{\text{measured}}$, $N(hkl)_{\text{unique}}$, R_{int} :	6862, 4688, 0.018
Criterion for I_{obs} , $N(hkl)_{\text{gt}}$:	$I_{\text{obs}} > 2 \sigma(I_{\text{obs}})$, 3871
$N(\text{param})_{\text{refined}}$:	354
Programs:	Bruker [1], SHELX [2]

Table 2: Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å²).

Atom	<i>x</i>	<i>y</i>	<i>z</i>	$U_{\text{iso}}^*/U_{\text{eq}}$
O1	1.05577(14)	0.31690(7)	0.19289(7)	0.0420(3)
O2	1.12495(12)	0.22906(8)	0.36611(6)	0.0360(2)
H2	1.2189	0.2281	0.3433	0.054*
O3	0.50126(13)	0.21694(8)	0.36264(7)	0.0430(3)
N1	0.81535(19)	0.69119(9)	-0.02533(8)	0.0431(3)
H1	0.8534	0.7118	-0.0721	0.052*
N2	0.76650(16)	0.35307(8)	0.22118(7)	0.0312(3)
N3	0.80410(14)	0.19376(8)	0.34729(7)	0.0276(2)
C1	0.5113(2)	0.79071(11)	-0.03781(9)	0.0413(4)
H1A	0.5184	0.8246	-0.0904	0.050*
C2	0.3618(2)	0.80656(12)	0.00410(11)	0.0470(4)
H2A	0.2649	0.8509	-0.0212	0.056*
C3	0.3525(2)	0.75725(12)	0.08416(11)	0.0488(4)
H3	0.2507	0.7704	0.1117	0.059*
C4	0.4913(2)	0.68950(11)	0.12308(10)	0.0412(3)
H4	0.4834	0.6570	0.1762	0.049*
C5	0.64436(19)	0.67045(10)	0.08126(9)	0.0320(3)
C6	0.6524(2)	0.72210(10)	0.00096(9)	0.0330(3)
C7	0.9074(2)	0.62201(11)	0.03528(11)	0.0429(4)
H7	1.0208	0.5898	0.0314	0.051*
C8	0.8100(2)	0.60677(10)	0.10202(9)	0.0360(3)
C9	0.8562(2)	0.53299(11)	0.17795(10)	0.0441(4)
H9A	0.8298	0.5648	0.2332	0.053*
H9B	0.9921	0.5178	0.1903	0.053*
C10	0.7342(2)	0.43218(10)	0.15125(9)	0.0369(3)
H10A	0.5989	0.4490	0.1379	0.044*
H10B	0.7610	0.4021	0.0955	0.044*
C11	0.61472(18)	0.33756(10)	0.27115(9)	0.0300(3)

<https://doi.org/10.1515/ncrs-2020-0257>

Received May 24, 2020; accepted June 10, 2020; available online July 14, 2020

Abstract

C₃₃H₂₉N₃O₃, triclinic, $P\bar{1}$ (no. 2), $a = 7.1229(8)$ Å, $b = 12.8851(13)$ Å, $c = 15.0472(15)$ Å, $\alpha = 92.354(2)^\circ$, $\beta = 103.338(2)^\circ$, $\gamma = 91.502(2)^\circ$, $V = 1341.7(2)$ Å³, $Z = 2$, $R_{\text{gt}}(F) = 0.0364$, $wR_{\text{ref}}(F^2) = 0.1074$, $T = 296(2)$ K.

CCDC no.: 2009028

The molecular structure is shown in the figure. Table 1 contains crystallographic data and Table 2 contains the list of the atoms including atomic coordinates and displacement parameters.

*Corresponding author: Meng Lan Lv, School of Chemical Engineering, Guizhou Institute of Technology, Guizhou 550003, P.R. China, e-mail: lvmenglan@git.edu.cn. <https://orcid.org/0000-0002-4516-9323>

Ying Fen Li, Xian Wei and Song Bai: School of Chemical Engineering, Guizhou Institute of Technology, Guizhou 550003, P.R. China

Table 2 (continued)

Atom	x	y	z	U_{iso}^*/U_{eq}
H11	0.4927	0.3265	0.2253	0.036*
C12	0.63777(17)	0.24360(10)	0.32988(8)	0.0289(3)
C13	0.95630(17)	0.20753(9)	0.29776(8)	0.0262(3)
C14	0.92629(18)	0.29877(10)	0.23300(8)	0.0290(3)
C15	0.59419(19)	0.43426(10)	0.32943(9)	0.0338(3)
C16	0.7512(2)	0.47782(13)	0.39306(11)	0.0516(4)
H16	0.8710	0.4480	0.4006	0.062*
C17	0.7309(3)	0.56593(14)	0.44580(12)	0.0643(5)
H17	0.8370	0.5948	0.4886	0.077*
C18	0.5551(3)	0.61054(14)	0.43504(13)	0.0651(5)
H18	0.5418	0.6695	0.4705	0.078*
C19	0.3999(3)	0.56832(14)	0.37238(15)	0.0658(5)
H19	0.2807	0.5988	0.3651	0.079*
C20	0.4180(2)	0.47988(12)	0.31911(12)	0.0497(4)
H20	0.3111	0.4515	0.2765	0.060*
C21	0.8224(2)	0.10543(10)	0.40939(9)	0.0350(3)
H21A	0.9286	0.0637	0.4006	0.042*
H21B	0.7053	0.0619	0.3924	0.042*
C22	0.8565(2)	0.13885(11)	0.50956(10)	0.0432(4)
C23	1.0352(3)	0.17620(15)	0.55799(12)	0.0684(5)
H23	1.1358	0.1822	0.5284	0.082*
C24	1.0677(4)	0.20509(18)	0.65068(14)	0.0925(8)
H24	1.1893	0.2307	0.6821	0.111*
C25	0.9255(6)	0.19635(18)	0.69508(15)	0.0953(9)
H25	0.9485	0.2160	0.7569	0.114*
C26	0.7470(5)	0.1586(2)	0.64936(17)	0.0974(9)
H26	0.6488	0.1520	0.6804	0.117*
C27	0.7108(3)	0.12975(17)	0.55583(13)	0.0729(6)
H27	0.5887	0.1045	0.5250	0.087*
C28	0.96301(18)	0.11024(9)	0.23576(8)	0.0294(3)
C29	1.1305(2)	0.08695(12)	0.20803(11)	0.0438(4)
H29	1.2441	0.1257	0.2325	0.053*
C30	1.1293(3)	0.00591(13)	0.14382(12)	0.0551(4)
H30	1.2415	−0.0083	0.1247	0.066*
C31	0.9640(3)	−0.05317(12)	0.10855(11)	0.0529(4)
H31	0.9640	−0.1070	0.0654	0.063*
C32	0.7979(2)	−0.03254(12)	0.13726(10)	0.0486(4)
H32	0.6864	−0.0735	0.1146	0.058*
C33	0.7969(2)	0.04945(11)	0.20009(9)	0.0380(3)
H33	0.6838	0.0637	0.2184	0.046*

Source of material

Benzaldehyde (2.0 mmol), 2-(1*H*-indol-3-yl)ethan-1-amine (2.0 mmol), 2-oxo-2-phenylacetic acid (2.0 mmol) and (isocyanomethyl)benzene (2.0 mmol) were mixed and stirred overnight in CH₃OH (2.5 mL) at room temperature. The reaction mixture was monitored by TLC. When the reaction was completed, the solvent was removed under reduced pressure. Then the crude residue was subjected to diisopropylamine (2.0 equiv.) and CH₃CN (3.0 mL) solution under microwave irradiation condition at 140 °C for 10 min. After the microwave vial was cooled to room temperature, the residue was purified by silica gel column chromatography

using a gradient of ethyl acetate/hexane (0–100%) to afford the title product.

Experimental details

A suitable crystal was selected and collected on a Bruker APEX-II CCD. All hydrogen atoms were added using a riding model using the default parameters of the SHELX program (Table 2).

Comment

Piperazine-2,5-diones are widely employed in drug discovery and typically exhibit a wide range of important biological activities [3]. The Ugi four-component reaction (U-4CR), followed by various post-condensation transformations, is well known as a versatile and highly efficient synthetic strategy for the preparation of cyclic compounds [4, 5]. We previously reported the use of this strategy to achieve the construction of various pyrazine compounds.

The asymmetric unit of the title compound contains one molecule. The bond lengths and angles in both crystallographically independent molecules are in the normal ranges [6]. In conclusion, we have developed a facile process for the synthesis of 1-(2-(1*H*-indol-3-yl)ethyl)-4-benzyl-3-hydroxy-3,6-diphenylpiperazine-2,5-dione using a Ugi four-component reaction. This facile procedure can be readily used to synthesize a diverse range of compounds for high throughput screening in medicinal chemistry.

Acknowledgements: This work was financially supported by the Natural Science Foundation of China (Grant No. 51973042), Excellent young scientific and technological talents of Guizhou, China (Grant No. QKHPTRC [2019]5652).

References

- BRUKER. SAINT, APEX2 and SADABS. Bruker AXS Inc., Madison, WI, USA (2009).
- Sheldrick, G. M.: Crystal Structure Refinement with SHELXL. *Acta Crystallogr.* **C71** (2015) 3–8.
- Welz, A.; Koba, M.: Piperazine derivatives as dangerous abused compounds. *Acta Pharm.* **70** (2020) 423–441.
- Li, Y.; Meng, J. P.; Lei, J.; Chen, Z. Z.; Tang, D. Y.; Zhu, J.; Zhang, J.; Xu, Z. G.: Efficient synthesis of fused oxazepino-isoquinoline scaffolds via an Ugi, followed by an intramolecular cyclization. *ACS Comb. Sci.* **19** (2017) 324–330.
- Song, G. T.; Meng, J. P.; Zhu, J.: Crystal structure of 2-(8-bromo-2-phenylimidazo[1,2- α]pyridin-3-yl)-6,7-dimethyl-3-phenylquinoxaline, C₂₉H₂₁BrN₄. *Z. Kristallogr. NCS* **233** (2018) 575–577.
- Govindaraju, T.; Pandeeswar, M.; Jayaramulu, K.; Jaipuria, G.; Atreya, H. S.: Spontaneous self-assembly of designed cyclic dipeptide (Phg-Phg) into two-dimensional nano- and mesosheets. *Supramol. Chem.* **23** (2011) 487–492.